U.S. House of Representatives Rush Holt Awards CytoSorbents Export Achievement Award

U.S. House of Representatives Rush Holt Awards CytoSorbents Export Achievement 
Award 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 01/27/14 --  CytoSorbents
Corporation (OTCQB: CTSO), a critical care immunotherapy company,
announced that U.S. House of Representatives Rush Holt awarded
CytoSorbents an Export Achievement Award from the U.S. Department of
Commerce and the International Trade Administration to recognize
CytoSorbents' recent accomplishments in the global marketplace.  
Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents,
stated, "It was an honor to accept the Export Achievement Award from
Congressman Holt at our offices and to discuss how our CytoSorb(R)
blood purification technology could potentially shape the future of
critical care medicine and reduce healthcare costs in the United
States. As a scientist who spent part of his academic career at
nearby Princeton University and as a staunch supporter of government
funding for scientific innovation, Congressman Holt was ideally
suited to appreciate our commercialization and research and
development accomplishments and to understand our goals for the
future." 
Vincent Capponi, Chief Operating Officer of CytoSorbents, remarked,
"We were pleased to receive this award. We have been working closely
with the U.S. Department of Commerce to investigate strategies to
mitigate our financial risk in global commerce including
participation in the Export-Import Bank (EXIM) program. With
increasing international interest in CytoSorb(R), this has allowed us
to aggressively expand our product distribution to countries such as
the United Kingdom, Ireland, the Netherlands, Turkey, Russia and
India, with more to come."  
Congressman Holt commented, "As our economy continues to recover,
manufacturers like CytoSorbents need the federal government to stand
by their sides -- to support basic scientific research and
development, and to create opportunities to export good ideas and
good products abroad. The Department of Commerce and the
Export-Import Bank help small companies find their way through
barriers to overseas markets." 
About CytoSorbents Corporation 
CytoSorbents is a critical care focused immunotherapy company using
blood purification to modulate inflammation -- with the goal of
preventing or treating multiple organ failure in life-threatening
illnesses. Organ failure is the cause of nearly half of all deaths in
the intensive care unit, with little to improve clinical outcome.
CytoSorb(R), the Company's flagship product, is approved in the
European Union as a safe and effective extracorporeal cytokine
filter, designed to reduce the "cytokine storm" that could otherwise
cause massive inflammation, organ failure and death in common
critical illnesses such as sepsis, burn injury, trauma, lung injury,
and pancreatitis. These are conditions where the risk of death is
extremely high, yet no effective treatments exist. CytoSorbents'
purification technologies are based on biocompatible, highly porous
polymer beads that can actively remove toxic substances from blood
and other bodily fluids by pore capture and surface adsorption.
CytoSorbents has numerous products under development based upon this
unique blood purification technology, protected by 32 issued US
patents and multiple applications pending, including HemoDefend(TM),
ContrastSorb, DrugSorb, and others. Additional information is
available for download on the Company's website:
http://www.cytosorbents.com/ 
Forward-Looking Statements 
This press release includes forward-looking statements intended to
qualify for the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements
in this press release are not promises or guarantees and are subject
to risks and uncertainties that could cause our actual results to
differ materially from those anticipated. These statements are based
on management's current expectations and assumptions and are
naturally subject to uncertainty and changes in circumstances. We
caution you not to place undue reliance upon any such forward-looking
statements. Actual results may differ materially from those expressed
or implied by the statements herein. Risk factors are detailed in the
Company's Form 10-K filed with the SEC on April 3, 2013, which is
available at http://www.sec.gov. 
Contact: 
Company 
CytoSorbents Corporation
Dr. Phillip Chan, MD, PhD
Chief Executive Officer 
(732) 329-8885 ext. *823
pchan@cytosorbents.com  
Investor Relations 
CytoSorbents Corporation
Amy Vogel
(732) 329-8885 ext. *777
avogel@cytosorbents.com 
 
 
Press spacebar to pause and continue. Press esc to stop.